“We expect to begin enrolling participants in the first quarter of 2026 for our norovirus challenge study evaluating CDI-988, our oral broad-spectrum protease inhibitor,” said Sam Lee, Ph.D., President and co-CEO of Cocrystal. “This study will provide an initial assessment of CDI-988 for both prevention and treatment of norovirus infection. Norovirus is a major cause of acute gastroenteritis and is highly contagious. It spreads rapidly in enclosed environments such as cruise ships, military bases, nursing homes, and hospitals. At present, there is no FDA-approved treatment or prevention for norovirus infection.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COCP:
- Cocrystal Pharma Completes $1.03M Private Placement
- Cocrystal Pharma completes $1.03M private placement
- Cocrystal Pharma’s CDI-988: A Promising Antiviral in Norovirus Treatment
- Cocrystal Pharma Secures NIH Award for Antiviral Research
- Cocrystal Pharma receives NIH SBIR award to advance influenza inhibitor program